Introduction
============

Atrial fibrillation (AF) is the most common cardiac dysrhythmia,^[@b1]--[@b2]^ with an estimated prevalence from \<0.5% in young adults to \>8% after the age of 80.^[@b3]^ Several population‐based studies in developed countries have suggested an increasing incidence and prevalence of AF.^[@b1],[@b4]--[@b5]^ Owing to the sustained prolongation of life expectancy and aging of the population, the proportion of patients with AF is expected to more than double in the next decades.^[@b1]^ These projections have been reported in several North American and European studies.^[@b1],[@b4],[@b6]--[@b8]^

AF is associated with significant morbidity and mortality.^[@b9]--[@b10]^ In particular, AF is associated with a 3‐ to 5‐fold increased risk of ischemic stroke, and the attributable risk of stroke associated with AF increases from 1.5% in subjects aged 50 to 59 years of age to 23.5% among those aged 80 to 89 years.^[@b3]^ The prevention of arterial thromboembolic events is therefore crucial in the management of AF and relies on the use of oral anticoagulants such as vitamin K antagonists. Recently, novel oral anticoagulants have entered the market and they are currently recommended for non‐valvular AF (NVAF) only,^[@b11]--[@b13]^ the most common form of AF in developed countries. In this context of increasing societal and economic burden of AF, and changing preventive therapeutic options for thromboembolic risk in NVAF, recent population‐based measures are necessary for effective prevention strategies and planning of health care resources. However, very few epidemiologic studies focused specifically on NVAF, included hospital‐diagnosed patients only, or were limited to a particular age or non‐treated subgroup. Therefore, we aimed to provide contemporary estimates of the incidence and mortality rates of NVAF in a well‐defined population‐based cohort of patients with incident NVAF in the province of Québec, Canada.

Methods
=======

Source of Data
--------------

This study was conducted using computerized heath care databases of the *Régie de l\'assurance maladie du Québec* (RAMQ), the *Maintenance et exploitation des données pour l\'étude de la clientèle hospitalière* (MED‐ÉCHO) and the *Institut de la statistique du Québec* (ISQ). The RAMQ is responsible for administering the universal health care services for all its residents currently living in the province of Québec. Health care coverage is mandatory for Québec residents. Visitors, non‐Canadian students, and individuals residing outside of Québec for \>183 days in the year are not eligible for coverage. In 2004, the calendar year used to estimate standardized rates in our study, 7 396 325 Québec residents were eligible for health coverage, 49% were men, 23% were 19 years old or younger, 58% were 20 to 59, and 19% were 60 or older.

The RAMQ has three computerized databases. The *demographic database* contains the age, sex, and postal code of all individuals registered. The *medical services database* contains information on the medical services program, including nature of the service rendered, specialty of treating and referring physician, date and location, as well as the diagnostic code of the service (International Classification of Diseases, 9th Revision, Clinical Modification \[ICD‐9‐CM\] or enhanced version of ICD‐10 for Canada ICD‐10‐CA). This program is universal for all Québec residents and is a fee‐for‐service. The *prescription database*, which was not used for this study, contains information on outpatient prescription medications. Since 1996, this program covers all Québec residents aged 65 years or older, welfare recipients, and individuals who do not have private medical insurance.

MED‐ÉCHO has maintained the *hospital inpatient database* since 1980. The database contains data pertaining to all Québec hospitalisations including date and type of admission and discharge, type of establishment, primary and secondary diagnoses, in addition to procedure codes (with corresponding procedure dates). Prior to 2006, diagnoses were classified according to the ICD‐9‐CM and procedures were coded according to the Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (CCDTC). Since 2006, diagnoses and procedures are coded according to ICD‐10‐CA and the Canadian Classification of Health Interventions (CCI), respectively. Finally, the *cause of death database* is administered by the *Institut de la statistique du Québec* (ISQ) and contains vital statistics such as the date of death, the medical code corresponding to the underlying cause of death, as well as the establishment where the death took place (if any).

Each of these databases contains the individual\'s *numéro d\'assurance‐maladie* (Health Insurance Number). This unique number, acquired at birth or at the time of residency, remains unchanged throughout the life of the individual and is used for record linkage within the RAMQ databases and the MED‐ECHO. The general accuracy of linkage between the prescription database and the medical services database was found to be 98.2%. The 1.8% rate of unfeasible linkages arises primarily from name changes, and the quality of the data has been documented.^[@b14]--[@b15]^

The study protocol was approved by the Research Ethics Committee of the Jewish General Hospital, Montreal, Canada.

Cohort Definition
-----------------

From the source population of all individuals in the RAMQ database, we first identified all patients with an inpatient or outpatient diagnosis for atrial fibrillation (ICD‐9: 427.3, 427.31, 427.32; ICD‐10: I48, I48.0, I48.1) between January 1, 2000 and December 31, 2009.

Cohort entry (time zero) for all patients was defined at the date of the first diagnosis of NVAF during the study period. If the diagnosis occurred during a hospitalization, cohort entry was set as the date of hospital discharge. To confirm the incident nature of the NVAF diagnosis, all subjects with any mention of AF in the 2 years prior to the cohort entry diagnosis were excluded. Patients with a history of valvular aortic or mitral heart disease, previous valvular repair or hyperthyroidism (either a treatment or a diagnosis) in the 2 years prior to cohort entry were also excluded.

All cohort members were followed until RAMQ deregistration, death, or the end of the study period (December 31, 2009), whichever occurred first. The occurrence of death was determined from RAMQ and ISQ. MED‐ÉCHO was used to identify in‐hospital deaths.

Data Analysis
-------------

The study cohort was characterized by tabulating cohort members by age, sex, comorbidities measured during the 2 years prior to cohort entry as well as the CHADS~2~ risk score (congestive heart failure, hypertension, age over 75 years, diabetes mellitus, prior stroke, or transient ischemic attack).^[@b16]^ Crude incidence rates of first NVAF episodes were calculated from the number of new cases of NVAF divided by the total person‐years at risk in the population of Québec eligible for RAMQ between 2000 and 2009. Incidence rates were age and sex standardized to the population of Québec eligible for RAMQ in 2004 ([www.ramq.gouv.qc.ca](http://www.ramq.gouv.qc.ca)). Crude and age‐adjusted incidence rate ratios (IRR), comparing rates among women and men, were estimated using Poisson regression. Thirty‐day case‐fatality was calculated using all‐cause deaths as the numerator and the number of patients with incident NVAF as the denominator, stratified by age and sex. Linear trends in the incidence of NVAF were assessed using Poisson regression with calendar year as a continuous variable.

Confidence intervals (CI) were calculated using a significance level of 5%. All statistical procedures were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC).

Results
=======

The source population included 309 556 subjects with at least one atrial fibrillation diagnosis code during the period 2000--2009. From these, we identified 243 800 patients satisfying cohort inclusion and exclusion criteria ([Figure 1](#fig01){ref-type="fig"}). [Table 1](#tbl01){ref-type="table"} describes the baseline characteristics of the cohort. The mean age at NVAF diagnosis was 71.5 years, 63% of the patients were 70 years or older at diagnosis, 52% were males, and the mean follow‐up was 3.46 years. With respect to CHADS~2~ score at baseline, 20.2% had a score of 0, 27.5% had a score of 1, 28.1% had a score of 2, 15.4% had a score of 3, and 8.8% had a score of 4 or higher. The most prevalent comorbidities at cohort entry were hypertension (56%), hyperlipidemia (35%), diabetes (25%), and congestive heart failure (21%). Comparing characteristics of men and women, 24% of males were 80 years or older at the time of diagnosis compared with 41% of the women. The prevalence of cardiovascular comorbidities was higher in men than in women except for hypertension. The occurrence of a previous stroke or transient ischemic attack was similar in both groups. The age‐specific incidence rates of NVAF are shown in [Table 2](#tbl02){ref-type="table"} and the corresponding age‐ and sex‐specific rates in [Figure 2](#fig02){ref-type="fig"}. The population‐based incidence of NVAF was 3.28 (95% CI, 3.27 to 3.29) per 1000 per year, increasing with age for men and women. The age‐ and sex‐adjusted (to the 2004 Québec population eligible to RAMQ) incidence rate was 3.24 (95% CI, 3.23 to 3.25) per 1000 per year. The incidence rate of NVAF was higher in men compared with women in virtually all age groups with a crude and age‐adjusted IRR of 1.13 (95% CI, 1.12 to 1.14) and 1.51 (1.50 to 1.52), respectively. There was no evidence of an increasing incidence of NVAF during the 10‐year study period (*P*=0.13).

###### 

Baseline Characteristics of the Incident NVAF Cohort

                                 All           Men     Women                               
  ------------------------------ ------------- ------- ------------- ------- ------------- -------
  Cohort size                    243 800               126 833       52.02   116 967       47.98
  Follow‐up (years), mean (SD)   3.46 (2.86)           3.48 (2.87)           3.45 (2.85)   
  Age (y)                                                                                  
  0 to 19                        1230          0.5     660           0.52    570           0.49
  20 to 29                       2487          1.02    1323          1.04    1164          1
  30 to 39                       4788          1.96    2840          2.24    1948          1.67
  40 to 49                       11 172        4.58    6914          5.45    4258          3.64
  50 to 59                       24 776        10.16   15 967        12.59   8809          7.53
  60 to 69                       45 985        18.86   28 669        22.60   17 316        14.8
  70 to 79                       73 973        30.34   39 586        31.21   34 387        29.4
  ≥80                            79 389        32.56   30 874        24.34   48 515        41.48
  Comorbidities at diagnosis                                                               
  Hypertension                   137 871       56.55   65 841        51.91   72 030        61.58
  Myocardial infarction          49 690        20.38   30 345        23.93   19 345        16.54
  Angina pectoris                45 301        18.58   26 191        20.65   19 110        16.34
  Congestive heart failure       51 886        21.28   27 557        21.73   24 329        20.8
  Diabetes                       59 937        24.58   33 169        26.15   26 768        22.89
  Hyperlipidemia                 86 517        35.49   48 564        38.29   37 953        32.45
  Vascular disease               28 321        11.62   17 505        13.80   10 816        9.25
  Prior stroke or TIA            20 149        8.26    10 211        8.05    9938          8.5
  Prior hemorrhage               2617          1.07    1409          1.11    1208          1.03
  Chronic renal failure          26 670        10.94   15 495        12.22   11 175        9.55
  Cancer                         46 249        18.97   27 267        21.50   18 982        16.23
  CHADS2 score                                                                             
  0                              49 214        20.19   29 654        23.38   19 560        16.72
  1                              67 100        27.52   37 019        29.19   30 081        25.72
  2                              68 445        28.07   32 363        25.52   36 082        30.85
  3                              37 590        15.42   17 799        14.03   19 791        16.92
  4                              15 454        6.34    7114          5.61    8340          7.13
  5                              4780          1.96    2315          1.83    2465          2.11
  6                              1217          0.5     569           0.45    648           0.55

NAVF indicates non‐valvular atrial fibrillation; TIA, transient ischemic attack.

###### 

Incidence Rates of Non‐Valvular Atrial Fibrillation Per 1000 Person‐Years, by Age

  Age (y)    NVAF Events   Person‐Years   Incidence Rate Per 1000 Per Year   Incidence Rate Ratio (95% CI)
  ---------- ------------- -------------- ---------------------------------- -------------------------------
  Overall    243 800       74 297 764     3.28 (3.27 to 3.29)                
  0 to 19    1230          17 300 850     0.07 (0.07 to 0.08)                1.00 (Reference)
  20 to 29   2487          9 391 349      0.26 (0.25 to 0.28)                3.72 (3.48 to 3.99)
  30 to 39   4788          10 360 523     0.46 (0.45 to 0.48)                6.50 (6.11 to 6.92)
  40 to 49   11 172        12 421 796     0.90 (0.88 to 0.92)                12.65 (11.93 to 13.42)
  50 to 59   24 776        10 585 383     2.34 (2.31 to 2.37)                32.92 (31.09 to 34.86)
  60 to 69   45 985        7 035 336      6.54 (6.48 to 6.60)                91.93 (86.88 to 97.29)
  70 to 79   73 973        4 700 614      15.74 (15.62 to 15.85)             221.35 (209.22 to 234.18)
  ≥80        79 389        2 501 913      31.73 (31.51 to 31.95)             446.32 (421.88 to 472.18)

NAVF indicates non‐valvular atrial fibrillation.

![Details of incident non‐valvular atrial fibrillation cohort definition. AF indicates atrial fibrillation; NAVF, non‐valvular atrial fibrillation.](jah3-3-e001402-g1){#fig01}

![Incidence rates of non‐valvular atrial fibrillation per 1000 person‐years stratified by age and sex.](jah3-3-e001402-g2){#fig02}

Among the cohort, 16 815 patients died at the time of the NVAF diagnosis (or during the entry NVAF hospitalisation) and overall, 22 325 died within 1 month of diagnosis. The most common causes of death in the 30 days following NVAF diagnostic were cardiac (28.5%), cancer (24%), pulmonary (9.5%), infections (7.3%), and stroke (6.4%). The corresponding 30‐day case‐fatality risk was 9.2% (95% CI 9.0 to 9.3), with 83% of these deaths occurring in the first week. Compared with women, men had a higher 30‐day case‐fatality (age‐standardized case‐fatality 10.0% (95% CI 9.8 to 10.1) and 8.46 (95% CI 8.30 to 8.61), respectively, *P*\<0.0001). As expected, the 30‐day case‐fatality increased steadily with CHADS~2~ score, ranging from 3.04% (95% CI 2.89 to 3.19) for a score of 1 to 26.79% (95% CI 24.30 to 29.28) for a score of 6, and was much higher for patients diagnosed in hospital, whether it was a primary or a secondary diagnosis ([Table 3](#tbl03){ref-type="table"}). Also, case‐fatality varied greatly according to associated comorbidities at the time of diagnosis, from 22.24% (95% CI 21.69 to 22.80) in patients with recent acute coronary syndrome, to 5.85% (95% CI 5.69 to 6.02) in patients with hypertension without cardiac or chronic kidney disease ([Table 4](#tbl04){ref-type="table"}). [Figure 3](#fig03){ref-type="fig"} describes the 30‐day case‐fatality stratified by age and sex, showing that the difference in case‐fatality was more pronounced in the elderly.

###### 

Crude Case‐Fatality in the 30 Days Following Atrial Fibrillation According to CHADS2 Score

                              CHADS~2~   People At Risk   Deaths   Case‐Fatality (%)   95% CI
  --------------------------- ---------- ---------------- -------- ------------------- ----------------
  Overall                     0          49 214           1496     3.04                2.89 to 3.19
  1                           67 100     4413             6.58     6.39 to 6.76        
  2                           68 445     6755             9.87     9.65 to 10.09       
  3                           37 590     5671             15.09    14.72 to 15.45      
  4                           15 454     2756             17.83    17.23 to 18.44      
  5                           4780       908              19.00    17.88 to 20.11      
  6                           1217       326              26.79    24.30 to 29.28      
  Outpatient NVAF diagnosis   0          37 533           304      0.81                0.72 to 0.90
  1                           42 276     968              2.29     2.15 to 2.43        
  2                           33 084     878              2.65     2.48 to 2.83        
  3                           11 152     420              3.77     3.41 to 4.12        
  4                           3567       140              3.92     3.29 to 4.56        
  5                           928        34               3.66     2.46 to 4.87        
  6                           165        14               8.48     4.23 to 12.74       
  Hospital NVAF diagnosis     0          11 681           1192     10.20               9.66 to 10.75
  1                           24 824     3445             13.88    13.45 to 14.31      
  2                           35 361     5877             16.62    16.23 to 17.01      
  3                           26 438     5251             19.86    19.38 to 20.34      
  4                           11 887     2616             22.01    21.26 to 22.75      
  5                           3852       874              22.69    21.37 to 24.01      
  6                           1052       312              29.66    26.90 to 32.42      
  Primary diagnosis           0          2454             25       1.02                0.62 to 1.42
  1                           3888       84               2.16     1.70 to 2.62        
  2                           4489       150              3.34     2.82 to 3.87        
  3                           2753       146              5.30     4.47 to 6.14        
  4                           969        62               6.40     4.86 to 7.94        
  5                           255        17               6.67     3.60 to 9.73        
  6                           61         10               16.39    7.10 to 25.68       
  Secondary diagnosis         0          9227             1167     12.65               11.97 to 13.33
  1                           20 936     3361             16.05    15.56 to 16.55      
  2                           30 872     5727             18.55    18.12 to 18.98      
  3                           23 685     5105             21.55    21.03 to 22.08      
  4                           10 918     2554             23.39    22.60 to 24.19      
  5                           3597       857              23.83    22.43 to 25.22      
  6                           991        302              30.47    27.61 to 33.34      

CI indicates confidence intervals.

###### 

Case‐Fatality in the 30 Days Following Atrial Fibrillation According to Associated Comorbidities

                                                   People at Risk   Deaths   Case‐Fatality (%)   95% CI
  ------------------------------------------------ ---------------- -------- ------------------- ----------------
  Acute coronary syndrome                          21 458           4773     22.24               21.69 to 22.80
  Heart failure                                    55 144           9523     17.27               16.95 to 17.58
  Chronic kidney disease                           27 673           5940     21.46               20.98 to 21.95
  Recent cardiac (and related structure) surgery   13 222           1384     10.47               9.95 to 10.99
  Cardiomyopathy                                   7921             854      10.78               10.10 to 11.46
  Hypertension[\*](#tf4-1){ref-type="table-fn"}    80 417           4708     5.85                5.69 to 6.02
  Other[\*](#tf4-2){ref-type="table-fn"}           77 707           3852     4.96                4.80 to 5.11

CI indicates confidence intervals.

This category included only patients without any of the diagnostics listed in the table except hypertension.

This category included only patients without any of the diagnostics listed in the table.

![Case‐fatality in the 30 days following atrial fibrillation stratified by age and sex.](jah3-3-e001402-g3){#fig03}

Discussion
==========

Using a large population‐based cohort of patients with a first diagnosis of NVAF, we provided contemporary estimates of the burden of disease in Québec in terms of incidence and mortality following NVAF diagnosis during the last decade. The mean age at diagnosis was 71.5 years and, as expected, a large number of patients had associated comorbidities. Nearly 10% of the patients died within a month following NVAF diagnosis, and up to 27% of the patients with a CHADS~2~ score of 6. Compared with women, men had a higher 30‐day case‐fatality in all age groups and the difference increased in older age groups.

Population‐based contemporary estimates of the incidence of NVAF are missing. Large studies estimated the incidence of AF overall and did not specifically assess NVAF. Moreover, comparison between studies is also hampered by the various settings for case identification (hospital or population‐based), as well as the different algorithms for AF definitions, and exclusion criteria. Regarding the incidence of AF overall, previous large population‐based studies conducted in the 80s and the early 90s reported estimates slightly lower or comparable to ours,^[@b2],[@b17]--[@b19]^ except the cardiovascular health study.^[@b20]^ More recent estimates of AF incidence from population‐based cohorts are in line with our results. All these previous cohorts included all AF whereas we focused specifically on NVAF; However, NVAF is the most common form of AF, which allows meaningful comparison between our respective estimates. A German study, which used health insurance data to estimate incidence rates of AF in 2008 by age and sex, reported results closely matching ours with a very low incidence rate of 0.06 per 1000 person‐years under the age of 20 and up to 24.4 for the 80 to 84 years age group.^[@b21]^ Two population‐based US studies, including all adults with a first AF diagnosis, reported very similar age‐ and sex‐adjusted rates of 3.5 per 1000 person‐years^[@b6]^ and 3.68 per 1000 person‐years in 2000.^[@b4]^ Only two studies, focusing on patients 65 years or older, reported higher age‐standardized incidence in this age group than ours (27.4 for 1000 person‐years and 28.4 for 1000 person‐years in 2007).^[@b22]--[@b23]^ All studies to date have confirmed the higher incidence of AF among men compared with women, as reported in our study focusing on NVAF, with an incidence rate ratio ranging from 1.5 to 1.8.^[@b4],[@b17]--[@b18]^

Our case‐fatality estimates are higher than those reported in a Scottish cohort of 22 968 patients hospitalized for incident AF between 1986 and 1995.^[@b24]^ A likely explanation lies in their cohort definition, which was restricted to patients hospitalized with a principal diagnosis of AF, whereas we selected all patients with a first diagnosis of AF, either as primary or secondary diagnosis. The handful number of studies that described all causes mortality shortly after AF diagnosis consistently pointed out the highest mortality rate immediately following diagnosis.^[@b23],[@b25]--[@b26]^ The mortality rate in the first month has been estimated around 10 per 100 person‐years in one study of Medicare beneficiaries 65 years and older, decreasing thereafter.^[@b23]^ In a Québec cohort of AF sampled from the RAMQ database, the decline in the survival curve was steepest in the first 2 months after diagnosis with a 6% probability of death.^[@b26]^ Two previous hospital‐based cohorts of incident AF, with \>10 years of follow‐up, also showed that the mortality rate was highest in the year following diagnosis.^[@b25],[@b27]^ We extend previous work by precisely quantifying all‐cause mortality in the first month following diagnosis in patients with NVAF only, and showing that case‐fatality varied greatly according to associated comorbidities at the time of NVAF diagnosis. We also provided case‐fatality estimates in all age‐strata including the younger age groups, and showed that case‐fatality after NVAF was higher in men than in women in all age groups, in agreement with the findings from the original Framingham heart study cohort of 5209 patients reporting Kaplan‐Meier death rates.^[@b9]^

Our study is based on one of the largest and complete population‐based cohort of patients diagnosed with NVAF in an outpatient and inpatient setting, allowing precise estimates of the incidence and mortality following NVAF diagnosis. Moreover, the use of an administrative database covering the entire Québec population excludes the possibility of selection bias. We applied broad exclusion criteria to define subjects with NVAF among all patients with AF diagnosis, as previously done.^[@b28]--[@b29]^ However, using less restrictive criteria such as excluding only subjects with mitral stenosis, valvular replacement, or prosthetic heart valve as done by others,^[@b1]^ hence privileging sensitivity over specificity of NVAF diagnosis, only resulted in minor changes to our results. Some limitations relate to the characteristics of the RAMQ database such as the inability to identify the different types of NVAF, paroxysmal, persistent, and permanent. In addition, it is possible that some patients were not true incident cases and had been diagnosed for some time before cohort entry. Physician billings for outpatient visit only contain one diagnostic code, limiting the medical information available for each medical visit. However, we also used the MED‐ÉCHO database, which allows up to 30 diagnostic codes for each hospital episode and all patients had a minimum of 2 years of information available before cohort entry to ensure sufficient baseline information to exclude prevalent cases. Finally, the prevalence of comorbidities at the time of diagnosis may have been underestimated for the same reason, especially for patients who did not have any hospital admission in the 2 years before cohort entry. However, the baseline comorbidities were also measured during the 2 years before cohort entry, which increases the likelihood of capturing most of the important chronic diseases. Also, some vascular risk factors such as smoking and body mass index are not routinely collected in the RAMQ database and their prevalence could not be estimated.

In conclusion, we provide precise and up‐to‐date estimates of the incidence of NVAF in a large well‐defined population‐based cohort, illustrating the significant burden related to NVAF. Mortality remains high in subjects with NVAF around the time of diagnosis, and case‐fatality increases with age, being constantly higher in men compared with women across all age categories.
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